½ÃÀ庸°í¼­
»óǰÄÚµå
1463146

ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : ÀÎÇ÷翣ÀÚ À¯Çüº°, Ä¡·áº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)

Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2024- 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 118 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 13¾ï 8,621¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

°èÀý¼º ÀÎÇ÷翣ÀÚ À¯Çà, Àü¿°¼º È£Èí±â ÁúȯÀÇ À¯Çà, ÀÎÇ÷翣ÀÚ °ü·Ã ÇÕº´Áõ ¹ßº´ À§ÇèÀÌ ³ôÀº ȯÀÚ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÀÎÇ÷翣ÀÚ È®»êÀ» ¾ïÁ¦Çϱâ À§ÇÑ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥°ú ÀÎÇ÷翣ÀÚ Á¶±â Áø´Ü ¹× Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ Àνİú °°Àº Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 9¿ù °Ç°­º¸È£¼¾ÅÍ(Centre for Health Protection)ÀÇ º¸°í¼­¿¡ µû¸£¸é, 2023³â 10¿ù¿¡ Á¤ºÎ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÌ ½ÃÀÛµÉ ¿¹Á¤À̸ç, ÀÌ¿¡ µû¶ó Á¤ºÎ´Â °èÀý¼º ÀÎÇ÷翣ÀÚ ¿¹¹æÁ¢Á¾À» ¹«·á·Î Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ºÐ¾ßÀÇ ¿¬±¸ °³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁö°í, ´õ ¸¹Àº Á¦¾àȸ»ç°¡ ¹ÙÀÌ·¯½ºÀÇ ¿©·¯ ´Ü°è¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ÀÎÇ÷翣ÀÚÀ» ´õ È¿À²ÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ´õ È¿°úÀûÀÎ Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿Á½ºÆ÷µå ´ëÇÐÀÌ 2023³â 10¿ù¿¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é, ¸Å³â ¾à 290,000¸í¿¡¼­ 650,000¸íÀÇ »ç¸ÁÀÚ¸¦ ¹ß»ý½ÃŰ´Â ÀÎÇ÷翣ÀÚ Ä¡·á¹ýÀ» ¿¬±¸Çϱâ À§ÇØ RECOVERY Æ®·¹ÀÏÀÌ È®´ëµÇ¾ú½À´Ï´Ù.

ÀÎÇ÷翣ÀÚ È®»ê¿¡ ´ëÀÀÇϱâ À§ÇØ º¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ç×¹ÙÀÌ·¯½ºÁ¦°¡ ÇÊ¿äÇÔ¿¡ µû¶ó °¢ Á¦¾à»çµéÀº Â÷¼¼´ë Ç×¹ÙÀÌ·¯½ºÁ¦¿Í °°Àº Çõ½ÅÀûÀÎ Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ Ç×¹ÙÀÌ·¯½ºÁ¦´Â È¿´ÉÀÌ Çâ»óµÇ°í, ¿©·¯ ÀÎÇ÷翣ÀÚ ±ÕÁÖ¿¡ ´ëÇØ ´õ ³ÐÀº Ȱ¼º ½ºÆåÆ®·³À» °¡Áö¸ç, ºÎÀÛ¿ëÀ» °¨¼Ò½ÃÄÑ ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ¼ö¿ä¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¸é¿ª ¹ÝÀÀÀ̳ª À¯ÀüÀû üÁú µî ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ µû¶ó ÀÎÇ÷翣ÀÚ Ä¡·á¸¦ Á¶Á¤ÇÏ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á°¡ ¹ßÀüÇϰí ÀÖ´Â °Íµµ Àü ¼¼°è Á¦Ç° ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù Àεµ °úÇÐ ¿¬±¸¼ÒÀÇ ¿¬±¸¿¡ µû¸£¸é, ÇÇÄݸ°»êÀº ÀÎÇ÷翣ÀÚÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúº´À» À¯¹ßÇÏ´Â ¹ÙÀÌ·¯½º¸¦ Â÷´ÜÇÒ ¼ö ÀÖÀ¸¸ç, ÀϺΠ¹ÙÀÌ·¯½º¼º ÁúȯÀ» ÅðÄ¡ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù.

ÀÎÇ÷翣ÀÚÄ¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ÀÎÇ÷翣ÀÚ AÇü ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ºÎ¹®Àº ¹ßº´·ü Áõ°¡¿Í ÀûÀýÇÑ Åõ¾àÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ³ôÀº Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿À¼¿Å¸¹Ìºñ¸£ Àλ꿰Àº ¿©·¯ ±ÕÁÖ¿¡ ´ëÇÑ ³ôÀº È¿À²¼º°ú À¯È¿¼º µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ´ëºÎºÐÀÇ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¿Â¶óÀÎ ¾à±¹ÀÇ ºÎ»óÀº ȯÀÚ¿¡°Ô Æí¸®ÇÔ°ú Á¢±Ù¼º µî ¿©·¯ °¡Áö ÀÌÁ¡À» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â ÀÎÇ÷翣ÀÚÀÇ À¯Çà°ú »õ·Î¿î Á¦Á¦ °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå ÀλçÀÌÆ®

  • ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå-À¯Åë ä³Î ÇöȲ
  • ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PESTEL ºÐ¼®
  • ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå À¯Åë ä³Î µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå µ¶°¨ À¯Çüº° ¼¼°è ½ÃÀå

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • AÇü µ¶°¨
  • BÇü µ¶°¨

Á¦6Àå Ä¡·áº° ¼¼°è ½ÃÀå

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • Baloxavir Marboxil
  • Oseltamivir Phosphate
  • ±âŸ

Á¦7Àå À¯Åë ä³Îº° ¼¼°è ½ÃÀå

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ±âŸ

Á¦8Àå Áö¿ªº° ¼¼°è ½ÃÀå

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
  • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-ºÏ¹Ì
    • ºÏ¹Ì : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, µ¶°¨ À¯Çüº°, 2019³â-2032³â
    • ºÏ¹Ì : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019³â-2032³â
    • ºÏ¹Ì : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, Ä¡·áº°, 2019³â-2032³â
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-¹Ì±¹
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-ij³ª´Ù
  • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-À¯·´
    • À¯·´ : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, µ¶°¨ À¯Çüº°, 2019³â-2032³â
    • À¯·´ : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019³â-2032³â
    • À¯·´ : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, Ä¡·áº°, 2019³â-2032³â
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-¿µ±¹
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-ÇÁ¶û½º
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-µ¶ÀÏ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-ÀÌÅ»¸®¾Æ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-½ºÆäÀÎ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-³×´ú¶õµå
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-·¯½Ã¾Æ
  • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå-¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, µ¶°¨ À¯Çüº°, 2019³â-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019³â-2032³â
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, Ä¡·áº°, 2019³â-2032³â
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - Áß±¹
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - Àεµ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ¸»·¹À̽þÆ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ÀϺ»
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - Àεµ³×½Ã¾Æ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - Çѱ¹
  • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, µ¶°¨ À¯Çüº°, 2019³â-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019³â-2032³â
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, Ä¡·áº°, 2019-2032³â
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - À̽º¶ó¿¤
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ³²¾ÆÇÁ¸®Ä«
  • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, µ¶°¨ À¯Çüº°, 2019³â-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2019³â-2032³â
    • ¶óƾ¾Æ¸Þ¸®Ä« : µ¶°¨ Ä¡·áÁ¦ ½ÃÀå, Ä¡·áº°, 2019³â-2032³â
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ¸ß½ÃÄÚ
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ºê¶óÁú
    • µ¶°¨ Ä¡·áÁ¦ ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª

Á¦9Àå °æÀï ±¸µµ

  • È®´ë¿Í Àμö ºÐ¼®
    • È®´ë
    • Àμö
  • ÆÄÆ®³Ê½Ê/Çù¾÷/°è¾à/°ø°³

Á¦10Àå ±â¾÷ °³¿ä

  • AbbVie(US)
  • AstraZeneca(UK)
  • Bayer AG(Germany)
  • Bharat Biotech(India)
  • BioCryst Pharmaceuticals(US)
  • Daiichi Sankyo(Japan)
  • Mylan(US)
  • Novartis AG(Switzerland)
  • Roche Diagnostics(Switzerland)
  • Sanofi SA(France)
  • Seqirus(Australia)
LSH 24.05.16

The global influenza medications market size is expected to reach USD 1,386.21 million by 2032, according to a new study by Polaris Market Research. The report "Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The proliferation of seasonal flu, greater prevalence of contagious respiratory illness, and increasing patient population who are at higher risk of developing flu-related complications, are key factors driving the market growth. Growing number of government initiatives like vaccination programs for controlling the spread of influenza and awareness regarding the importance of early diagnosis and treatment of influenza, are further anticipated to propel market growth.

For instance, according a report by the Centre for Health Protection in September 2023, the Government Vaccination Programme was launched in October 2023 under which the government continued to provide seasonal influenza vaccination for free of cost.

Furthermore, growing research & development activities in the field of influenza medications and growing number of pharmaceutical companies implementing on the development of more effective antiviral drugs that can treat influenza more efficiently through targeting different stages of viral, are further boosting the market's growth. For instance, according to a report by the University of Oxford in October 2023, the RECOVERY trail has been expanded for investigating treatments for influenza that cause deaths of approx. 290,000 to 650,000 people each year.

As the need for effective and safer antiviral drugs to combat the spread of influenza, companies are introducing innovative antiviral drugs like next-generation antiviral drugs which offer enhanced efficacy, broader spectrum of activity against the several influenza strains, and reduced side effects, which is impacting the demand for influenza medications in a positive way.

Additionally, ongoing advances in personalized medicine tailoring to influenza treatment based on individual patient characteristics like immune response and genetic make-up, further escalating the product demand globally. For instance, according to a study done by the Indian Institute of Science in July 2023, it is reported that picolinic acid has the potential to block various disease-causing viruses including influenza and it also help to fight against several viral diseases.

Influenza Medications Market Report Highlights

Influenza A segment accounted for notable share, owing to rising incidences and awareness regarding the importance of proper medications

Oseltamivir phosphate segment held the majority share, that is attributed to its advantages including higher efficiency and effectiveness against several strains

Online pharmacies segment will grow at highest pace, emergence of online pharmacy platforms offering several benefits to patients like convenience and easy accessibility

North America dominated the market, on account of prevalence of influenza and rising investments in R&D activities to develop new formulations

The key market players include Bayer, Roche Diagnostics, Novartis, Sanofi, AstraZeneca, AbbVie, BioCryst Pharmaceuticals, and Mylan

Polaris Market Research has segmented the influenza medications market report based on influenza type, treatment, distribution channel, and region:

Influenza Medications, Influenza Type Outlook (Revenue - USD Million, 2023 - 2032)

  • Influenza A
  • Influenza B

Influenza Medications, Treatment Outlook (Revenue - USD Million, 2023 - 2032)

  • Baloxavir Marboxil
  • Oseltamivir Phosphate
  • Others

Influenza Medications, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Influenza Medications, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Influenza Medications Market Insights

  • 4.1. Influenza Medications Market - Distribution Channel Snapshot
  • 4.2. Influenza Medications Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising incidences of influenza and increasing awareness about public health
      • 4.2.1.2. Increased R&D efforts and growing regulatory
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Seasonal demand and availability of alternative treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Influenza Medications Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Influenza Medications Market, by Influenza Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
  • 5.3. Influenza A
    • 5.3.1. Global Influenza Medications Market, by Influenza A, by Region, 2019-2032 (USD Million)
  • 5.4. Influenza B
    • 5.4.1. Global Influenza Medications Market, by Influenza B, by Region, 2019-2032 (USD Million)

6. Global Influenza Medications Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
  • 6.3. Baloxavir Marboxil
    • 6.3.1. Global Influenza Medications Market, by Baloxavir Marboxil, by Region, 2019-2032 (USD Million)
  • 6.4. Oseltamivir Phosphate
    • 6.4.1. Global Influenza Medications Market, by Oseltamivir Phosphate, by Region, 2019-2032 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Influenza Medications Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Influenza Medications Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospitals Pharmacies
    • 7.3.1. Global Influenza Medications Market, by Hospitals Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Influenza Medications Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Influenza Medications Market, by Online Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.6. Others
    • 7.6.1. Global Influenza Medications Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Influenza Medications Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Influenza Medications Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Influenza Medications Market - North America
    • 8.3.1. North America: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
    • 8.3.2. North America: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.3.4. Influenza Medications Market - U.S.
      • 8.3.4.1. U.S.: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.3.5. Influenza Medications Market - Canada
      • 8.3.5.1. Canada: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
  • 8.4. Influenza Medications Market - Europe
    • 8.4.1. Europe: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.4. Influenza Medications Market - UK
      • 8.4.4.1. UK: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.5. Influenza Medications Market - France
      • 8.4.5.1. France: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.6. Influenza Medications Market - Germany
      • 8.4.6.1. Germany: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.7. Influenza Medications Market - Italy
      • 8.4.7.1. Italy: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.8. Influenza Medications Market - Spain
      • 8.4.8.1. Spain: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.9. Influenza Medications Market - Netherlands
      • 8.4.9.1. Netherlands: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.4.10. Influenza Medications Market - Russia
      • 8.4.10.1. Russia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
  • 8.5. Influenza Medications Market - Asia Pacific
    • 8.5.1. Asia Pacific: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.4. Influenza Medications Market - China
      • 8.5.4.1. China: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.5. Influenza Medications Market - India
      • 8.5.5.1. India: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.6. Influenza Medications Market - Malaysia
      • 8.5.6.1. Malaysia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.7. Influenza Medications Market - Japan
      • 8.5.7.1. Japan: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.8. Influenza Medications Market - Indonesia
      • 8.5.8.1. Indonesia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.5.9. Influenza Medications Market - South Korea
      • 8.5.9.1. South Korea: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
  • 8.6. Influenza Medications Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.4. Influenza Medications Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.5. Influenza Medications Market - UAE
      • 8.6.5.1. UAE: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.6. Influenza Medications Market - Israel
      • 8.6.6.1. Israel: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.6.7. Influenza Medications Market - South Africa
      • 8.6.7.1. South Africa: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
  • 8.7. Influenza Medications Market - Latin America
    • 8.7.1. Latin America: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.4. Influenza Medications Market - Mexico
      • 8.7.4.1. Mexico: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.5. Influenza Medications Market - Brazil
      • 8.7.5.1. Brazil: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
    • 8.7.6. Influenza Medications Market - Argentina
      • 8.7.6.1. Argentina: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie (US)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca (UK)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bayer AG (Germany)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bharat Biotech (India)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. BioCryst Pharmaceuticals (US)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Daiichi Sankyo (Japan)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Mylan (US)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Novartis AG (Switzerland)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche Diagnostics (Switzerland)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sanofi SA (France)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Seqirus (Australia)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦